FDA issues warning letters to 25 telehealth firms over misleading compounded GLP-1 marketing

The U.S. Food and Drug Administration has sent warning letters to 25 telehealth companies. The letters cite concerns about how the firms promote compounded GLP-1 drugs used for weight loss.

The agency says the companies are making false and misleading claims in their marketing materials. It alleges that the information presented to patients does not accurately reflect the safety, efficacy, or regulatory status of the compounded products.

The FDA action highlights growing regulatory focus on telehealth providers and their promotion of off‑label or compounded therapies. Companies may need to revise their advertising practices to avoid further enforcement actions.